Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Intercept Pharmaceuticals Company

ICPT
US45845P1084
A1J5U0

Price

19.00
Today +/-
+0
Today %
+0 %
P

Intercept Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Intercept Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Intercept Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Intercept Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Intercept Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Intercept Pharmaceuticals Stock Price History

DateIntercept Pharmaceuticals Price
11/14/202319.00 undefined
11/13/202319.00 undefined

Intercept Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Intercept Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Intercept Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Intercept Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Intercept Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Intercept Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Intercept Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Intercept Pharmaceuticals’s growth potential.

Intercept Pharmaceuticals Revenue, EBIT and net profit per share

DateIntercept Pharmaceuticals RevenueIntercept Pharmaceuticals EBITIntercept Pharmaceuticals Net Income
2030e435.7 M undefined42.36 M undefined9.81 M undefined
2029e505.24 M undefined96.34 M undefined50.96 M undefined
2028e344.04 M undefined97.12 M undefined65.39 M undefined
2027e354.64 M undefined101.85 M undefined68.83 M undefined
2026e370.63 M undefined116.5 M undefined71.08 M undefined
2025e368.73 M undefined107.98 M undefined73.88 M undefined
2024e368.48 M undefined102.71 M undefined87.25 M undefined
2023e337.77 M undefined-45.95 M undefined-55.73 M undefined
2022285.71 M undefined-68.22 M undefined221.82 M undefined
2021260.75 M undefined-100.69 M undefined-91.43 M undefined
2020312.7 M undefined-218.6 M undefined-274.9 M undefined
2019252 M undefined-312.4 M undefined-344.7 M undefined
2018179.8 M undefined-285.5 M undefined-309.2 M undefined
2017131 M undefined-335.6 M undefined-360.4 M undefined
201625 M undefined-402.5 M undefined-412.8 M undefined
20152.8 M undefined-229.2 M undefined-226.4 M undefined
20141.7 M undefined-113.2 M undefined-283.2 M undefined
20131.6 M undefined-39.5 M undefined-67.8 M undefined
20122.4 M undefined-18.9 M undefined-46.3 M undefined
20111.8 M undefined-13.8 M undefined-15.7 M undefined
20100 undefined-16.4 M undefined-18 M undefined

Intercept Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e2030e
01211225131179252312260285337368368370354344505435
--100.00-50.00-100.001,150.00424.0036.6440.7823.81-16.679.6218.259.20-0.54-4.32-2.8246.80-13.86
-------98.4798.8898.0298.4099.6299.65--------
000000012917724730725928400000000
-16-13-18-39-113-229-402-335-285-312-218-100-68-45102107116101979642
--1,300.00-900.00-3,900.00-11,300.00-11,450.00-1,608.00-255.73-159.22-123.81-69.87-38.46-23.86-13.3527.7229.0831.3528.5328.2019.019.66
-18-15-46-67-283-226-412-360-309-344-274-91221-558773716865509
--16.67206.6745.65322.39-20.1482.30-12.62-14.1711.33-20.35-66.79-342.86-124.89-258.18-16.09-2.74-4.23-4.41-23.08-82.00
19.219.26.31820.823.724.725.128.531.73331.8933.8400000000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Intercept Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Intercept Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2010201120122013201420152016201720182019202020212022
                         
15.417.7110.2144.8239.7628.1689.4414.9436.2652.6469.7419.69485.57
0000009.116.525.73841.528.3426.86
0000003.22.100000
0000000000000
0.10.61.11.43.59.96.114.820.630.634.559.9927.7
15.518.3111.3146.2243.2638707.8448.3482.5721.2545.7508.02540.13
0.90.30.11.75.91011.316.210.418.418.76.846.11
0000000000000
0000000000000
0000000000000
0000000000000
0.40.30.31.12.5420.119.916.315.116.112.177.48
1.30.60.42.88.41431.436.126.733.534.819.0113.58
16.818.9111.7149251.6652739.2484.4509.2754.7580.5527.02553.71
                         
000000000003042
0.070.070.180.270.71.31.431.491.82.182.232.312.24
-61.8-74.5-118.2-186-469.2-695.6-1,108.5-1,469.5-1,778.8-2,123.5-2,398.3-2,489.77-2,136.89
-200-2000100-300-2,300-2,800-800-2,300-1,100-2,500-2,873-8,256
0000000000000
8.3-2.665.982.4230.9602.1314.916.41951.5-166.9-183.9693.08
0.50.61.23.23.14.26.7711.81924.617.614.23
1.10.92.62.2411.426.634.627.862.583.141.0742.73
0.12.49.23.58.131.845.262.574.680.571.4109.4963.55
0000000000000
0.30.10000000000109.57
24138.915.247.478.5104.1114.2162179.1168.16230.08
0.100000341.4355.7371.3532.1560.6539.78223.1
0000000000000
6.81833.35986.24.58.34.69.27.73.047.45
6.91833.35986.2345.9364375.9541.3568.3542.82230.56
8.92246.367.923.253.6424.4468.1490.1703.3747.4710.99460.63
17.219.4112.2150.3254.1655.7739.3484.5509.1754.8580.5527.02553.71
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Intercept Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Intercept Pharmaceuticals's financial health and stability.

Assets

Intercept Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Intercept Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Intercept Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Intercept Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2010201120122013201420152016201720182019202020212022
-15-12-43-67-283-226-412-360-309-344-274-91221
0000013443320
0000000000000
01300021814-2192-1921
22314821474104132116141160101-249
0000000000000
0000000000005
-132-15-28-87-162-342-265-240-236-170-41-26
000-1-4-5-5-100-1-300
00-64-70-96-389-60287-48-18816270261
00-64-68-91-383-55298-47-18716671262
0000000000000
00000044700223078-268
25010866190565522652361-751
24010866190565414226345701-267
-------38.00--2.00-2.00-1.00-1.00-
0000000000000
10227-326121026-2631-928-38
-13.692.55-15.79-29.64-92.38-168.84-347.52-275.79-240.88-237.75-173.92-41.46-27.35
0000000000000

Intercept Pharmaceuticals stock margins

The Intercept Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Intercept Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Intercept Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Intercept Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Intercept Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Intercept Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Intercept Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Intercept Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Intercept Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Intercept Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Intercept Pharmaceuticals Margin History

Intercept Pharmaceuticals Gross marginIntercept Pharmaceuticals Profit marginIntercept Pharmaceuticals EBIT marginIntercept Pharmaceuticals Profit margin
2030e99.66 %9.72 %2.25 %
2029e99.66 %19.07 %10.09 %
2028e99.66 %28.23 %19.01 %
2027e99.66 %28.72 %19.41 %
2026e99.66 %31.43 %19.18 %
2025e99.66 %29.28 %20.04 %
2024e99.66 %27.87 %23.68 %
2023e99.66 %-13.6 %-16.5 %
202299.66 %-23.88 %77.64 %
202199.54 %-38.62 %-35.06 %
202098.31 %-69.91 %-87.91 %
201998.33 %-123.97 %-136.79 %
201898.61 %-158.79 %-171.97 %
201798.93 %-256.18 %-275.11 %
201699.66 %-1,610 %-1,651.2 %
201599.66 %-8,185.71 %-8,085.71 %
201499.66 %-6,658.82 %-16,658.82 %
201399.66 %-2,468.75 %-4,237.5 %
201299.66 %-787.5 %-1,929.17 %
201199.66 %-766.67 %-872.22 %
201099.66 %0 %0 %

Intercept Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Intercept Pharmaceuticals earnings per share therefore indicates how much revenue Intercept Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Intercept Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Intercept Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Intercept Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Intercept Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Intercept Pharmaceuticals Revenue, EBIT and net profit per share

DateIntercept Pharmaceuticals Sales per ShareIntercept Pharmaceuticals EBIT per shareIntercept Pharmaceuticals Earnings per Share
2030e10.42 undefined0 undefined0.23 undefined
2029e12.08 undefined0 undefined1.22 undefined
2028e8.23 undefined0 undefined1.56 undefined
2027e8.48 undefined0 undefined1.65 undefined
2026e8.86 undefined0 undefined1.7 undefined
2025e8.82 undefined0 undefined1.77 undefined
2024e8.81 undefined0 undefined2.09 undefined
2023e8.08 undefined0 undefined-1.33 undefined
20228.44 undefined-2.02 undefined6.56 undefined
20218.18 undefined-3.16 undefined-2.87 undefined
20209.48 undefined-6.62 undefined-8.33 undefined
20197.95 undefined-9.85 undefined-10.87 undefined
20186.31 undefined-10.02 undefined-10.85 undefined
20175.22 undefined-13.37 undefined-14.36 undefined
20161.01 undefined-16.3 undefined-16.71 undefined
20150.12 undefined-9.67 undefined-9.55 undefined
20140.08 undefined-5.44 undefined-13.62 undefined
20130.09 undefined-2.19 undefined-3.77 undefined
20120.38 undefined-3 undefined-7.35 undefined
20110.09 undefined-0.72 undefined-0.82 undefined
20100 undefined-0.85 undefined-0.94 undefined

Intercept Pharmaceuticals business model

Intercept Pharmaceuticals Inc is a biotechnology company based in New York City that focuses on the discovery and development of therapeutics for the treatment of chronic liver diseases. The company was founded in 2002 and has since brought a variety of innovative drugs to the market. The business model of Intercept Pharmaceuticals Inc is based on the invention, development, and marketing of drugs that specifically target certain disease conditions. They primarily focus on the development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These two diseases are prevalent worldwide and pose significant health problems in many Western societies. Intercept Pharmaceuticals Inc has already achieved significant success in the treatment of NAFLD and NASH. The various divisions of Intercept Pharmaceuticals Inc can be divided into research, development of new products, sale of existing drugs, and collaboration with partners and other companies. In research, the company strives to develop the most effective and safe medications, utilizing state-of-the-art technologies and research methods. The main products of Intercept Pharmaceuticals Inc are Ocaliva and obeticholic acid. Ocaliva is a medication used to treat primary biliary cholangitis, a disease that causes inadequate movement of bile through the liver and its accumulation in the body. Ocaliva helps improve bile production and alleviate the symptoms of this disease. Obeticholic acid is a new approach to the treatment of NASH and is currently being tested in clinical trials. Intercept Pharmaceuticals Inc works closely with other companies and organizations to ensure the most effective therapy for patients worldwide. Interaction with industry colleagues, scientific institutions, and experts in the field of medical research allows for faster development of new products that benefit patients. Overall, Intercept Pharmaceuticals Inc has achieved an impressive track record in recent years. The company has established a strong position in the field of liver diseases by advancing research and development in innovative ways. The focus on NAFLD and NASH allows Intercept Pharmaceuticals Inc to play a leading role in this market segment and provide patients with effective medications for their conditions. In summary, Intercept Pharmaceuticals Inc is a company dedicated to the development and marketing of products for the treatment of liver diseases. Through the use of innovative technologies and close collaboration with other companies and organizations, Intercept Pharmaceuticals Inc has already achieved significant success in the development of new medications. The company has established a strong position in this market segment and aims to develop further innovative products to combat liver diseases in the future. Intercept Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Intercept Pharmaceuticals SWOT Analysis

Strengths

Intercept Pharmaceuticals Inc has a strong portfolio of innovative drugs targeting liver diseases, positioning the company as a key player in this specific therapeutic area. Their focus on these diseases allows for specialized expertise and superior understanding of patient needs.

The company has successfully developed and commercialized Ocaliva, an FDA-approved medication for the treatment of primary biliary cholangitis, generating significant revenues and establishing themselves as a leader in this indication. This success demonstrates Intercept Pharmaceuticals' ability to bring novel drugs to market.

Weaknesses

One of Intercept Pharmaceuticals' key weaknesses is their heavy reliance on Ocaliva for revenue generation. As the majority of their revenue comes from this single drug, any issues like patent expiration, competition, or safety concerns could significantly impact the company's financial performance.

Another weakness is the limited diversification of their product portfolio. While focused on liver diseases, a lack of additional drugs for different indications may hinder growth opportunities and leave the company vulnerable to shifts in market dynamics.

Opportunities

Intercept Pharmaceuticals has the opportunity to expand their presence in the liver disease therapeutic area by developing and commercializing additional drugs to complement Ocaliva. By leveraging their expertise, they can target other hepatobiliary diseases and expand their customer base.

The growing global prevalence of liver diseases, such as nonalcoholic steatohepatitis (NASH), presents a significant market opportunity for Intercept Pharmaceuticals. By capitalizing on this trend, they can tap into a larger patient population and drive revenue growth.

Threats

Intercept Pharmaceuticals faces intense competition from other pharmaceutical companies that aim to develop liver disease treatments. The entry of new players or the emergence of alternative therapies could erode the company's market share and pose a threat to their revenue stream.

Regulatory challenges can also pose a threat to Intercept Pharmaceuticals. Changes in FDA regulations or safety concerns related to their products may lead to delays in drug approvals or restrictions on usage, impacting the company's ability to bring new drugs to market effectively.

Intercept Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Intercept Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Intercept Pharmaceuticals shares outstanding

The number of shares was Intercept Pharmaceuticals in 2023 — This indicates how many shares 33.837 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Intercept Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Intercept Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Intercept Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Intercept Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Intercept Pharmaceuticals.

Intercept Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.45 0.08  (117.78 %)2023 Q3
6/30/2023-0.52 -0.14  (73.01 %)2023 Q2
3/31/2023-0.66 -0.77  (-16.56 %)2023 Q1
12/31/2022-0.16 -0.5  (-203.58 %)2022 Q4
9/30/20224.7 7.8  (66.01 %)2022 Q3
6/30/2022-0.5 -0.68  (-36.77 %)2022 Q2
3/31/2022-0.92 -0.58  (36.95 %)2022 Q1
12/31/2021-1.12 -1.23  (-9.94 %)2021 Q4
9/30/2021-1.11 -0.63  (43.37 %)2021 Q3
6/30/2021-1.24 -0.33  (73.43 %)2021 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Intercept Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

59

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Intercept Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
9.99814 % State Street Global Advisors (US)4,180,2241,125,7146/30/2023
9.56709 % Genextra S.p.A.4,000,00009/2/2022
5.63680 % BlackRock Institutional Trust Company, N.A.2,356,74760,3976/30/2023
4.96985 % Deerfield Management Company, L.P.2,077,8932,077,8936/30/2023
4.95389 % The Vanguard Group, Inc.2,071,222-2,615,5849/29/2023
4.22557 % BlackRock Financial Management, Inc.1,766,7111,210,9046/30/2023
3.25155 % UBS Financial Services, Inc.1,359,4711,236,3236/30/2023
3.09378 % Caligan Partners, LP1,293,5101,293,5106/30/2023
2.77781 % Citi Investment Research (US)1,161,401763,9366/30/2023
2.28415 % Pictet Asset Management Ltd.955,005260,3686/30/2023
1
2
3
4
5
...
10

Intercept Pharmaceuticals Executives and Management Board

Dr. Mark Pruzanski55
Intercept Pharmaceuticals Director (since 2002)
Compensation 6.43 M
Mr. Jerome Durso55
Intercept Pharmaceuticals President, Chief Executive Officer, Director (since 2017)
Compensation 4.46 M
Mr. David Ford55
Intercept Pharmaceuticals Chief Human Resource Officer
Compensation 1.91 M
Dr. M. Michelle Berrey56
Intercept Pharmaceuticals President of Research and Development; Chief Medical Officer
Compensation 1.61 M
Mr. Andrew Saik53
Intercept Pharmaceuticals Chief Financial Officer
Compensation 1.39 M
1
2
3
4

Intercept Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Nuvo Pharmaceuticals Stock
Nuvo Pharmaceuticals
SupplierCustomer0,49-0,03-0,35-0,300,08-
Omnicom Stock
Omnicom
SupplierCustomer0,470,24-0,07-0,080,03-0,83
Certara Stock
Certara
SupplierCustomer-0,19-0,01-0,05-0,190,05-
1

Most common questions regarding Intercept Pharmaceuticals

What values and corporate philosophy does Intercept Pharmaceuticals represent?

Intercept Pharmaceuticals Inc is a company known for its strong values and corporate philosophy. The company is committed to delivering innovative treatments and solutions for patients with liver and other metabolic diseases. Intercept Pharmaceuticals Inc places a high emphasis on scientific rigor, integrity, and patient-focused approaches. With an unwavering dedication to quality and excellence, the company strives to provide breakthrough therapies to improve the lives of individuals worldwide. By continuously pushing boundaries and investing in cutting-edge research, Intercept Pharmaceuticals Inc is shaping the future of medical advancements in hepatology and beyond.

In which countries and regions is Intercept Pharmaceuticals primarily present?

Intercept Pharmaceuticals Inc is primarily present in the United States and Europe. As a renowned pharmaceutical company, Intercept has established its presence in major countries and regions within these continents. The company has successfully expanded its operations and is actively engaged in conducting clinical trials, seeking regulatory approvals, and commercializing its innovative therapeutics in these markets. With its headquarters located in New York City, Intercept Pharmaceuticals Inc continues to thrive and enhance its footprint in the healthcare industry across various countries and regions, providing innovative solutions and improving patient outcomes.

What significant milestones has the company Intercept Pharmaceuticals achieved?

Intercept Pharmaceuticals Inc has achieved significant milestones in its history. One of the notable achievements is the FDA approval of its drug Ocaliva® (obeticholic acid) in 2016, for the treatment of primary biliary cholangitis (PBC). This approval marked a major breakthrough in the treatment options for PBC patients. Additionally, Intercept Pharmaceuticals Inc has made progress in clinical trials for its drug candidate, OCA, which is being evaluated for the treatment of nonalcoholic steatohepatitis (NASH). The company has also expanded its global presence, actively collaborating with healthcare professionals and researchers to advance liver disease management. Intercept Pharmaceuticals Inc continues to strive for further innovation and development within the pharmaceutical industry.

What is the history and background of the company Intercept Pharmaceuticals?

Intercept Pharmaceuticals Inc is a biopharmaceutical company headquartered in New York, USA. Founded in 2002, Intercept focuses on the development and commercialization of innovative therapeutics to treat progressive liver diseases. The company's primary focus is on developing treatments for non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other liver diseases. Intercept made significant advancements with its flagship drug, Ocaliva, which received regulatory approvals for treating PBC and advanced fibrosis due to NASH. With a dedicated team of researchers and clinical experts, Intercept Pharmaceuticals Inc continues to expand its pipeline and strive for breakthrough treatments in the field of liver diseases.

Who are the main competitors of Intercept Pharmaceuticals in the market?

The main competitors of Intercept Pharmaceuticals Inc in the market are AbbVie Inc., Gilead Sciences Inc., and Bristol-Myers Squibb Company.

In which industries is Intercept Pharmaceuticals primarily active?

Intercept Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Intercept Pharmaceuticals?

The business model of Intercept Pharmaceuticals Inc revolves around developing and commercializing innovative therapeutics to address unmet medical needs in the field of liver and other related diseases. The company focuses on developing novel small molecule drugs to treat chronic liver diseases like nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other liver fibrosis-related conditions. Intercept Pharmaceuticals is committed to advancing scientific research and improving patients' lives by introducing effective treatment options. With a strong pipeline of potential therapies, the company aims to establish itself as a leader in the liver disease pharmaceutical market.

What is the P/E ratio of Intercept Pharmaceuticals 2024?

The Intercept Pharmaceuticals P/E ratio is 7.37.

What is the P/S ratio of Intercept Pharmaceuticals 2024?

The Intercept Pharmaceuticals P/S ratio is 1.74.

What is the Quality Investing of Intercept Pharmaceuticals?

The Quality Investing for Intercept Pharmaceuticals is 6/10.

What is the revenue of Intercept Pharmaceuticals 2024?

The expected Intercept Pharmaceuticals revenue is 368.48 M USD.

How high is the profit of Intercept Pharmaceuticals 2024?

The expected Intercept Pharmaceuticals profit is 87.25 M USD.

What is the business model of Intercept Pharmaceuticals

Intercept Pharmaceuticals Inc. is a global biotechnology company focused on the discovery, development, and commercialization of therapeutics for the treatment of chronic liver diseases and other metabolic disorders. The company was founded in 2002 and is headquartered in New York City. Intercept's business strategy is based on identifying and developing innovative therapy approaches for treating various diseases that represent significant medical needs worldwide. The company's product portfolio focuses on the development of drugs specifically targeting the enzyme that is the main cause of liver diseases and other metabolic disorders. Intercept Pharmaceuticals' flagship product is Ocaliva (Obeticholic Acid), an FXR agonist for the treatment of primary biliary cholangitis (PBC). PBC is a rare chronic inflammatory liver disease in which the immune system attacks and destroys the bile ducts in the liver. Ocaliva is the first medication approved by the FDA for the treatment of PBC after choleretic therapy. In addition to Ocaliva, Intercept Pharmaceuticals is also working on the development of other drugs for the treatment of liver diseases and other metabolic disorders. Another promising product is INT-767, a dual FXR/TGR5 agonist being developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Intercept Pharmaceuticals is also pursuing a comprehensive clinical development strategy to find new applications and indications for its products. The company collaborates closely with patient organizations, universities, and companies to support the research of liver diseases and other metabolic disorders. Intercept Pharmaceuticals also has a strong presence in the global market. The company has entered into distribution partnerships with leading pharmaceutical companies worldwide to bring its products to market faster and more reliably. In the United States, Ocaliva is distributed in collaboration with the Japanese pharmaceutical company Sumitomo Dainippon Pharma. In Europe, Intercept Pharmaceuticals works with the French company Genfit. In addition to its product development and distribution strategy, Intercept Pharmaceuticals is also heavily involved in research and development. The company invests significant resources in researching new technologies and therapeutics to expand its product range and identify new applications. Intercept Pharmaceuticals collaborates closely with leading universities and research institutions worldwide to advance its research agenda. Overall, Intercept Pharmaceuticals' business model aims to develop and bring innovative therapies for the treatment of liver diseases and other metabolic disorders to market. The company pursues a comprehensive development strategy and collaborates closely with other companies and institutions to drive innovation. Intercept Pharmaceuticals is on a promising growth trajectory and has the potential to become a leading provider of therapeutics for liver diseases and other metabolic disorders.

What is the Intercept Pharmaceuticals dividend?

Intercept Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Intercept Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Intercept Pharmaceuticals or the company does not pay out a dividend.

What is the Intercept Pharmaceuticals ISIN?

The ISIN of Intercept Pharmaceuticals is US45845P1084.

What is the Intercept Pharmaceuticals WKN?

The WKN of Intercept Pharmaceuticals is A1J5U0.

What is the Intercept Pharmaceuticals ticker?

The ticker of Intercept Pharmaceuticals is ICPT.

How much dividend does Intercept Pharmaceuticals pay?

Over the past 12 months, Intercept Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intercept Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Intercept Pharmaceuticals?

The current dividend yield of Intercept Pharmaceuticals is .

When does Intercept Pharmaceuticals pay dividends?

Intercept Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intercept Pharmaceuticals?

Intercept Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Intercept Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intercept Pharmaceuticals located?

Intercept Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intercept Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intercept Pharmaceuticals from 10/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/9/2024.

When did Intercept Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/9/2024.

What was the dividend of Intercept Pharmaceuticals in the year 2023?

In the year 2023, Intercept Pharmaceuticals distributed 0 USD as dividends.

In which currency does Intercept Pharmaceuticals pay out the dividend?

The dividends of Intercept Pharmaceuticals are distributed in USD.

All fundamentals about Intercept Pharmaceuticals

Our stock analysis for Intercept Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intercept Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.